Valuation: Arvinas, Inc.

Market Cap 487M 435M 406M 369M 695M 47.12B 700M 4.88B 1.91B 23.97B 1.83B 1.79B 77.04B P/E 2026 *
-331x
P/E 2027 * -2.14x
Enterprise Value 36.39M 32.51M 30.33M 27.55M 51.89M 3.52B 52.28M 364M 142M 1.79B 137M 134M 5.75B EV / Sales 2026 *
0.12x
EV / Sales 2027 * 2.81x
Free-Float
79.97%
Yield 2026 *
-
Yield 2027 * -
1 day+1.92%
1 week-3.68%
Current month-3.68%
1 month-20.66%
3 months-13.27%
6 months-34.48%
Current year-37.18%
1 week 7.22
Extreme 7.22
7.52
1 month 7.22
Extreme 7.22
9.1
Current year 6.97
Extreme 6.97
14.51
1 year 6.97
Extreme 6.97
14.51
3 years 5.9
Extreme 5.9
53.08
5 years 5.9
Extreme 5.9
97.33
10 years 5.9
Extreme 5.9
108.46
Manager TitleAgeSince
Chief Executive Officer 47 12/02/2026
Director of Finance/CFO 56 24/06/2024
Chief Tech/Sci/R&D Officer 58 17/06/2024
Director TitleAgeSince
Chairman 66 15/06/2023
Director/Board Member 64 01/07/2018
Chairman 67 12/02/2026
Date Insider Type Main position Quantity % Market Cap. Importance
21/5/26 Sell

Chief Executive Officer

-2,209 0.0035%
11/5/26 Sell

Chief Financial Officer

-11,139 0.0174%
11/5/26 Sell

Chief Technology Officer

-11,108 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
+1.92%-3.68%-19.89%-60.97% 487M
+4.16%+4.16%+49.37%+94.17% 74.68B
-15.38%-15.71%+3.23%+51.91% 58.7B
-1.82%+1.18%+4.11%+32.21% 48.36B
+0.50%-2.14%+331.33%+702.20% 43.05B
-0.72%-3.99%+28.50%+29.94% 42.48B
+0.34%-0.52%+6.56%+109.35% 41.39B
-0.11%+1.96%+9.19%+52.66% 31.29B
-0.50%-3.10%-10.19%-14.35% 23.93B
-3.32%-10.86%-37.32%+316.28% 22.22B
Average -1.50%-2.33%+36.49%+131.34% 38.66B
Weighted average by Cap. -1.98%-1.57%+49.22%+144.78%

Financials

2026 *2027 *
Net sales 296M 265M 247M 224M 422M 28.64B 425M 2.97B 1.16B 14.57B 1.11B 1.09B 46.83B 64.19M 57.36M 53.51M 48.61M 91.54M 6.21B 92.23M 643M 251M 3.16B 241M 236M 10.15B
Net income -666K -595K -555K -505K -950K -64.46M -957K -6.68M -2.61M -32.78M -2.5M -2.45M -105M -248M -221M -207M -188M -353M -23.98B -356M -2.48B -970M -12.19B -930M -910M -39.2B
Net Debt -451M -403M -376M -341M -643M -43.6B -648M -4.52B -1.76B -22.18B -1.69B -1.66B -71.29B -307M -274M -256M -232M -438M -29.68B -441M -3.07B -1.2B -15.09B -1.15B -1.13B -48.53B
Projected Income Statement - Annual - Arvinas, Inc.
Logo Arvinas, Inc.
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Employees
246
Date Price Change Volume
07/10/26 USD 7.450 +1.92% 601,836
06/10/26 USD 7.310 -2.01% 585,799
05/10/26 USD 7.460 +0.67% 628,531
02/10/26 USD 7.410 -0.27% 585,123
01/10/26 USD 7.430 -3.94% 807,321
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Ratings Surperformance© - Arvinas, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
7.450USD
Average target price
13.93USD
Spread / Average Target
+86.96%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Arvinas, Inc.
  1. Stock Market
  2. Stocks
  3. ARVN Stock